Covenant Emerges From Secrecy With $250 Million Funding for New Cruise Missile
Covenant, a stealthy startup developing a new type of cruise missile, has officially emerged from a period of intense secrecy, announcing it has raised $250 million. Founded in 2024 by Israeli-American Michael Kaufman, the company aims to produce a cruise missile, dubbed Anthem, that is significantly cheaper and faster to manufacture than existing systems like the U.S. Tomahawk.
The substantial funding round, which reportedly valued the company at over $1 billion in its latest stage, saw participation from major defense-tech investors including Andreessen Horowitz's American Dynamism fund, Peter Thiel's Founders Fund, 8VC, Lux Capital, Lightspeed, and Israel's Aleph.
Covenant has already secured $150 million in supply contracts with U.S. and European defense entities and a $70 million contract with the U.S. Navy for a maritime version of Anthem and export adaptation. The company anticipates further orders by year-end. Serial production is slated to begin in the first quarter of 2027, with a target output of 5,000 units annually.
The Anthem missile system is designed for rapid, large-scale production to address the rapid depletion of long-range precision missile stocks observed in recent conflicts. "Anthem is designed to enable hitting these targets even when fighting continues over time. To maintain deterrence, one must maintain a sufficiently large stock of munitions and be able to replenish it at the required pace," stated Kaufman.
The company, registered in the U.S. with headquarters in Washington D.C., operates R&D and manufacturing facilities in Israel's north, Dallas, Texas, and Saxony, Germany. It employs approximately 200 people across these locations, with ongoing recruitment in all three countries.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.